Tykerb and Clozaril among formal Japanese approvals
This article was originally published in Scrip
Japan's ministry of health, labour and welfare has formally approved a number of products given positive recommendations by an advisory committee last month, including GlaxoSmithKline's Tykerb and Novartis's Clozaril.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.